Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

"This is a sad day for democracy and a sad day for our judicial system," the justice minister said in a statement. Information ...

Vice President Jagdeep Dhankhar expressed hope that the entire country would soon adopt the Uniform Civil Code (UCC), following Uttarakhand's implementation of it. He criticized those opposing the ...

US President Donald Trump announced plans to build a domestic version of Israel’s Iron Dome missile defence system. This new project will aim to protect the US from various missile threats.

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...

Virgin Voyages has kicked off 2025 with a bang, with a 60 percent increase in revenue and a 40 percent jump in new bookings. MSC Cruises is bringing its fourth World-class ship to a world class ...